Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: Results from the SIMAP database study

Current Medical Research and Opinion

Volumn 24, Issue 1, 2008, Pages 261-266

  Berto, Patrizia ^a,b   Frati, Franco ^c,d   Incorvaia, Cristoforo ^e   Cadario, Gianni ^f   Contiguglia, Rosario ^g   Di Gioacchino, Mario ^h   Puccinelli, Paola ^d   Senna, Gian Enrico ⁱ   Valle, Carla ^j  

^a UNIVERSITY OF PADOVA   (Italy)

^b Pbe Consulting   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d Medical and Scientific Department   (Italy)

^e ICP Hospital   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g ASL 5   (Italy)

^h UNIVERSITY OF CHIETI   (Italy)

ⁱ General Hospital   (Italy)

^j SAN PAOLO HOSPITAL   (Italy)

more..

Author keywords

Costs; Economic evaluation; Respiratory allergy; Sublingual immunotherapy

Indexed keywords

ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CETIRIZINE; DESLORATADINE; EBASTINE; FLUTICASONE; FORMOTEROL; IMMUNOMODULATING AGENT; LEVOCETIRIZINE; LORATADINE; MOMETASONE FUROATE; SALBUTAMOL; SALMETEROL; STEROID;

ADULT; ALLERGY; ARTICLE; ASTHMA; CONTROLLED STUDY; DATA BASE; FEMALE; GRASS POLLEN; HEALTH CARE COST; HUMAN; IMMUNOTHERAPY; ITALY; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; RHINITIS;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; ASTHMA; CASE-CONTROL STUDIES; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POACEAE; RHINITIS, ALLERGIC, SEASONAL;

EID: 38549106545     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X253726     Document Type: Article

References (24)

1. The National Health Service health technology assessment programme. Available from http://www.hta.ac.uk [Last accessed 17 Aug 2006]
2. The National Health Service health technology assessment programme. Available from http://www.hta.nhsweb.nhs.uk [Last accessed 17 Aug 2006]
3. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003:CD001186
4. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003:CD002893
5. Olaguibel JM, Alvarez-Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusion from one meta-analysis. J Invest Allergol Clin Immunol 2005;15:9-16
6. Calamita Z, Saconato H, Pela AB, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane Collaboration method. Allergy 2006;61:1162-72
7. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97:141-8
8. Bousquet J, van Cauwenberge P, editors. Allergic rhinitis and its impact on asthma (ARIA). Position Paper endorsed by WHO. J Allergy Clin Immunol 2001;108(Suppl 5):147-334
9. Ministero della Sanità. Nomenclatore Tariffario delle prestazioni ambulatoriali DM 22.7.96; Gazzetta Ufficiale n 216, 14.9.96
10. Giofil Database of Drug Prices. Available from http://www.giofil.it [Last accessed 20 May 2006]
11. Stallergenes, data on file, 2006
12. ISPOR Real World Task Force. ISPOR using 'real world' data task force draft report. Available from http://www.ispor.org/workpaper/real_world_data.asp [Last accessed 22 Aug 2006]
13. Ariano R, Berto P, Tracci D, et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006;27:159-63
14. Buchner K, Siepe M. Nutzen der Hyposensibilierung unter wirtschaftlichen Aspekten. Allergo J 1995;4:156-63
15. Fischer P. Therapie des allergisches Asthma. Die spezifische Hyposensibilierung kann helfen Kosten in Milliardenhohe einzusparen. Laryngo-Rhino-Otologie 1995;74:28
16. Le Pen C, Rumeau-Pichen C, Lillin H. L'impact de l'immunothérapie specifique sur le couts directs de la maladie allergique: une etude pragmatique. Rev Franc All Immunol Clin 1997:37:11-14
17. Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000;17:37-52
18. Berto P, Bassi M, Incorvaia C, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Allerg Immunol (Paris) 2005;37:303-8
19. Berto P, Passalacqua G, Crimi N, et al. Economic Evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol 2006;97:615-21
20. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med 1999;159:941-55
21. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006;354:1985-97
22. Bollettino polline. Available from http://www.pollineallergia.net [Last accessed 13 Sept 2007]
23. Di Rienzo V, Pucci S, D'Alò S, et al. Effects of high-dose sublingual immunotherapy on quality of life in patients with cypress-induced rhinitis: a placebo-controlled study. Clin Exp Allergy Rev 2006;6:67-70
24. Ariano R, Amoroso S, Astarita C, et al. Quality of life in allergic rhinitis and impact of high-dose sublingual immunotherapy: a real-life study. Clin Exp Allergy Rev 2006;71-73